Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista plus anti-VEGF regimens for neovascular age-related macular degeneration
2013-005549-35Phase 2Active
- Sponsor
- Barcelona Macula Foundation
- Start
- Jan 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegpleranib, ranibizumab, bevacizumab and aflibercept in exudative macular degeneration (3 arms), sponsored by Barcelona Macula Foundation. Primary endpoints: Safety, tolerability and development of subfoveal fibrosis and Safety endpoints. Started Jan 2014; status: active.
02
Drugs
pegpleranibranibizumabbevacizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-005549-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005549-35.